Rebecca Araujo

DocwireNews

Researchers from the Karolinska Institutet in Stockholm, Sweden, evaluated the efficacy of the BCL-2 inhibitor venetoclax for the treatment of relapsed/refractory multiple myeloma (MM).&nbsp;The findings from this study were published in the <a href="https://onlinelibrary.wiley.com/doi/10.1002/ajh.26207">American Journal of Hematology</a>.&ldquo;Although currently not Food and Drug Administration (FDA)-approved to treat [patients with] MM, there is a growing number of reports indicating its efficacy as a salvage therapy for these patients, especially for those with the t(11;14) chromosomal marker,&rdquo; explained the study authors. &ldquo;These studies, however, have also indicated that venetoclax given at doses &ge;400 mg/day can cause serious adverse events (AEs) especially when administered with bortezomib, commonly related to infections.&rdquo;For this retrospective study, the researchers evaluated outcomes for 22 patients with relapsed/refractory MM treated with a venetoclax-based quadruplet regimen at their institution. Patients received oral venetoclax 100&ndash;250 mg daily in combination with low-dose bortezomib, daratumumab, and dexamethasone. All patients had previously received a proteasome inhibitor and the majority (96%) received an immunomodulator prior to venetoclax initiation. The median number of prior lines of treatment was 3, and median follow-up was 9 months.<h2>Partial response or better in one-third of patients</h2>Overall, 6 patients (33%) achieved a partial response or better to treatment. The median time on treatment was 7.2 months. For patients who achieved at least a partial response, median treatment has not yet been met, with a minimum treatment length of 15 months. There was no difference in baseline characteristics between patients who did and did not achieve at least a partial response.Ten patients in the cohort had the t(11;14) <a href="https://www.docwirenews.com/urban-health-today/urban-health-multiple-myeloma-knowledge-hub/urban-health-multiple-myeloma-picks/study-finds-racial-bias-in-myeloma-biomarker-testing/">chromosomal marker</a>. The overall response rate for patients without this chromosomal marker was 31%, compared to 80% of patients with the marker.Treatment-emergent AEs occurred in 20 patients (80%). According to the investigators, all cases were manageable and there were no deaths associated with treatment. Neutropenia was reported in 28% of patients, and thrombocytopenia also occurred in 28% of patients. The most common non-hematologic AE was nausea, occurring in 32% of patients.<h2>Predicting venetoclax response via IHC stains</h2>In addition to examining treatment outcomes, the investigators also examined whether immunohistochemical (IHC) stains on bone marrow samples were predictive of response. The team evaluated bone marrow samples from 20 patients before and after treatment with venetoclax. They found no significant difference in CD138-positive MM cells between patients who achieved at least a partial response and those who did not. The ratio of frequency of BCL2 and MCL1 expression was significantly higher among patients that achieved at least a partial response (P=0.031). These findings were similar across a cohort of samples from patients with newly diagnosed MM (P=0.028).&ldquo;The current study demonstrates that venetoclax is effective in the treatment of heavily pre-treated [patients with MM]&hellip;with mild side effects,&rdquo; wrote the study authors in conclusion. &ldquo;Our data also highlight the importance of using molecular markers for the prediction of response to treatment with venetoclax. We show that the usage of IHC on bone marrow samples, at any stage of the disease and before the exposure to venetoclax, can provide clinicians with a simple tool to predict responses in MM patients with t(11;14).&rdquo;

BMI Modifies the Relationship Between Glycemic Status and Asthma Severity in Children

Asthma

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Latest News

Venetoclax Quadruplet Regimen Is Active in Patients with Refractory MM

Oncology

Researchers from the Karolinska Institutet in Stockholm, Sweden, evaluated the efficacy of the BCL-2 inhibitor venetoclax for the treatment of relapsed/refractory multiple ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe